| 3.37 -0.14 (-3.99%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.16 | 1-year : | 5.92 |
| Resists | First : | 4.42 | Second : | 5.07 |
| Pivot price | 3.73  |
|||
| Supports | First : | 3.36 | Second : | 2.8 |
| MAs | MA(5) : | 3.52 |
MA(20) : | 3.91 |
| MA(100) : | 4.67 |
MA(250) : | 7.15 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 9.3 |
D(3) : | 13.3 |
| RSI | RSI(14): 33.8 |
|||
| 52-week | High : | 20 | Low : | 3.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PASG ] has closed above bottom band by 18.1%. Bollinger Bands are 16.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.78 - 3.8 | 3.8 - 3.82 |
| Low: | 3.32 - 3.35 | 3.35 - 3.37 |
| Close: | 3.33 - 3.37 | 3.37 - 3.4 |
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.
Sat, 24 Oct 2026
Passage Bio, Inc. Estimates – NASDAQ:PASG - TradingView
Wed, 21 Oct 2026
Passage Bio, Inc. (Nasdaq – PASG), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE - StreetInsider
Wed, 21 Oct 2026
PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
Tue, 20 Oct 2026
Passage Bio amends merger terms: what it means for Passage Bio stock - AD HOC NEWS
Tue, 13 Oct 2026
Passage BIO, Inc. SEC Filing (Oct 13, 2026) - Stock Titan
Thu, 25 Jun 2026
PASG Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 7.7 (%) |
| Held by Institutions | 46.3 (%) |
| Shares Short | 91 (K) |
| Shares Short P.Month | 102 (K) |
| EPS | -11.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.7 % |
| Return on Equity (ttm) | -169.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -11.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.3 |
| PEG Ratio | 0 |
| Price to Book value | 2.44 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|